Greenspring Advisors’s AstraZeneca AZN Stock Holding History

Greenspring Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Buy	1,685 +303	+22%	+$57K	0.02%	254
2026 Q1	$273K	Buy	+1,382	New	+$266K	0.02%	245

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Greenspring Advisors's AZN Position: Q2 2026 in Review

Greenspring Advisors increased its AstraZeneca (AZN) stake by 22% in Q2 2026, buying an estimated $57K and bringing the position to 1,685 shares worth $319K. The position accounts for 0.02% of the portfolio, ranked #254.

Greenspring Advisors first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Greenspring Advisors held 1,685 shares of AstraZeneca worth $319K as of Q2 2026.
Greenspring Advisors bought 303 AstraZeneca shares in Q2 2026, an estimated $57K.
AstraZeneca made up 0.02% of Greenspring Advisors's portfolio in Q2 2026, its #254 holding.
Greenspring Advisors first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Greenspring Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.